News | June 07, 2011

Solution for Expanding Clinical Utilization in Nuclear Cardiology

June 7, 2011 – At the Society of Nulear Medicine (SNM) 2011 meeting this week, Siemens Healthcare demonstrated how users of the Symbia S and Symbia T series, single-photon emission computed tomography (SPECT) and SPECT•CT systems, respectively, are taking advantage of IQ•SPECT, to dramatically reduce the length of imaging protocols. A field-upgradeable combination of hardware and software, IQ•SPECT is helping nuclear cardiologists cut the cardiac imaging protocol from approximately 20 minutes to less than five minutes. These shortened exams enable a sustainable approach to nuclear cardiology that potentially enables decreased radiation dose to patients, assists to make the procedure more tolerable for the elderly, provides high quality diagnostic information, and allows users to better utilize an imaging resource that is hampered by limited availability of the key radiotracer.

“There is a significant difference between a four-minute SPECT scan with IQ•SPECT and a conventional 20-minute SPECT because many older patients cannot tolerate a longer scan; in our practice IQ•SPECT provides the opportunity to obtain quality SPECT imaging information in cases where it would not have been possible to even attempt imaging,” said James R. Corbett, M.D., director, cardiovascular nuclear medicine, professor, departments of internal medicine and radiology, University Hospital, University of Michigan Health System, Ann Arbor.

In recognition of its market-differentiating features, Siemens recently received the Product Differentiation Excellence Award, Nuclear Cardiology, North America, 2011, from industry analyst group Frost & Sullivan.

“Despite the benefits to clinical decision making conferred by the modality, the cardiac SPECT market has been faced with challenging circumstances that have led to a significant shift in the traditional provider setting,” said Sangeetha Prabakar, industry analyst, Frost & Sullivan. “With IQ•SPECT, Siemens has delivered a solution that addresses the cost sensibilities engendered by decreased reimbursement and the relative scarcity of the radiotracer.”

IQ•SPECT brings enhanced value to patients, medical facilities, and cardiologists and is an ideal fit for hospital-based cardiology imaging needs. It has been shown to reduce radiotracer doses by up to 50 percent, thus translating into lower amounts of radiation for the patient, and potential increased cost savings and access to radiotracer supply for the medical facility.

IQ•SPECT utilizes SmartZoom collimators, which focus on the heart, collecting up to four times more counts than conventional, large-bore, parallel-hole collimators; cardio-centric orbit acquisition, which ensures that the heart is always in the SmartZoom collimator’s “sweet spot,” or magnification zone, as opposed to the gantry’s mechanical center; and, lastly, a proprietary 3-D reconstruction algorithm that models the position of each of the 48,000 collimator holes on each detector, allowing state-of-the-art distant-dependent isotropic (3-D) resolution recovery, CT-based attenuation correction (when using SPECT•CT), and energy window-based scatter correction.

For more information:

Related Content

CZT SPECT camera detectors offered by GE.

A display of CZT SPECT gamma camera detectors at RSNA 2016. These detectors are more sensitive than those used in older cameras, allowing for faster scans or lower radiation dose. 

Feature | Nuclear Imaging | September 19, 2017 | Dave Fornell
Cardiac nuclear myocardial perfusion imaging (MPI) has been a mature area of imaging for years, but has recently star
Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
Videos | Nuclear Imaging | August 24, 2017
Randy Thompson, M.D., attending cardiologist, St.
cardiac nuclear myocardial perfusion imaging (MIP) exam guidelines for women
News | Nuclear Imaging | June 15, 2017
June 15, 2017 — The American Society of Nuclear Cardiology (ASNC) has published an updated consensus statement on evi
Videos | Nuclear Imaging | April 28, 2017
David Wolinsky, M.D., director of nuclear cardiology at Cleveland Clinic Florida and past-president of the American S
IBA Molecular, acquisition, Mallinckrodt Nuclear Imaging, nuclear imaging
News | Nuclear Imaging | January 30, 2017
IBA Molecular has successfully completed its acquisition of Mallinckrodt Nuclear Imaging, announced in August 2016,...
Medrad Intego PET Infusion System, recall
News | Nuclear Imaging | January 12, 2017
January 12, 2017 — Bayer Healthcare has initiated a recall of all its Medrad Intego PET Infusion System Source Admini
Nuclear cardiology, dose reduction, myocardial perfusion imaging
News | Nuclear Imaging | January 05, 2017
January 5, 2017 — Working in concert, the American Society of Nuclear Cardiology (ASNC), the Intersocietal Accreditat
PET, F-18 florbetaben, cardiac amyloidosis, Princess Alexandria Hospital

In a pilot study, F-18-florbetaben PET imaging appeared promising for differentiating between cardiac amyloidosis and hypertensive heart disease. Image courtesy of W. Phillip Law/Princess Alexandra Hospital, Brisbane, Australia.

News | Nuclear Imaging | December 06, 2016
Researchers at Princess Alexandra Hospital, Brisbane, Australia, have demonstrated that cardiac amyloidosis (abnormal...
Overlay Init